Posted by Michael Wonder on 16 Mar 2021
Health Canada approves Perjeta for use pre-surgery in patients with aggressive early breast cancer
16 March 2021 - New approval provides Canadian patients with HER2 positive early breast cancer a proven treatment regimen in a neo-adjuvant setting where meaningful reductions in tumour size can have long-term survival benefits.
Roche Canada is pleased to announce today that Health Canada has granted market authorization to Perjeta (pertuzumab for injection) as a neo-adjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive).
